Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

The rechallenge strategy is based on the concept that a subset of patients with RAS wild‐type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor receptor (EGFR) inhibition, after progression to an anti‐EGFR based‐therapy. We performed a pooled analysis of two‐pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Martini, G., Ciardiello, D., Famiglietti, V., Rossini, D., Antoniotti, C., Troiani, T., Napolitano, S., Esposito, L., Latiano, T. P., Maiello, E., Del Re, M., Lonardi, S., Aprile, G., Santini, D., Masi, G., Avallone, A., Normanno, N., Pietrantonio, F., Pinto, C., Ciardiello, F., Cremolini, C., Martinelli, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166888/
https://www.ncbi.nlm.nih.gov/pubmed/36880426
http://dx.doi.org/10.1002/cam4.5699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166888/
https://www.ncbi.nlm.nih.gov/pubmed/36880426
http://dx.doi.org/10.1002/cam4.5699

Ejemplares similares